Healthcare provider profile · identity verified

Janet Satterthwaite

Nurse Practitioner · INDIANAPOLIS, IN · NPI 1831729383

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	140	45
Atorvastatin Calcium	Atorvastatin Calcium	126	49
Gabapentin	Gabapentin	124	47
Warfarin Sodium	Warfarin Sodium	118	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	112	41
Furosemide	Furosemide	111	36
Levothyroxine Sodium	Levothyroxine Sodium	99	32
Amlodipine Besylate	Amlodipine Besylate	77	28
Nystatin	Nystatin	74	27
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	74	18
Prednisone	Prednisone	73	39
Omeprazole	Omeprazole	65	25
Ondansetron Odt	Ondansetron	64	25
Potassium Chloride	Potassium Chloride	64	23
Pantoprazole Sodium	Pantoprazole Sodium	62	20
Trazodone Hcl	Trazodone Hcl	62	23
Ciprofloxacin Hcl	Ciprofloxacin Hcl	61	44
Diclofenac Sodium	Diclofenac Sodium	59	26
Buspirone Hcl	Buspirone Hcl	56	22
Eliquis	Apixaban	54	17
Fluticasone Propionate	Fluticasone Propionate	52	25
Metoprolol Succinate	Metoprolol Succinate	50	23
Alprazolam	Alprazolam	49	19
Azithromycin	Azithromycin	47	34
Carvedilol	Carvedilol	46	14
Hydroxyzine Hcl	Hydroxyzine Hcl	44	21
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	44	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	43	31
Fluconazole	Fluconazole	41	26
Metoprolol Tartrate	Metoprolol Tartrate	40	12
Lisinopril	Lisinopril	39	15
Mirtazapine	Mirtazapine	39	11
Tramadol Hcl	Tramadol Hcl	39	18
Montelukast Sodium	Montelukast Sodium	37	12
Duloxetine Hcl	Duloxetine Hcl	36	13
Metformin Hcl	Metformin Hcl	36	13
Sertraline Hcl	Sertraline Hcl	36	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	36	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	13
Ozempic	Semaglutide	35	11
Allopurinol	Allopurinol	34	suppressed
Donepezil Hcl	Donepezil Hcl	34	11
Bupropion Xl	Bupropion Hcl	32	suppressed
Olanzapine	Olanzapine	32	suppressed
Ondansetron Hcl	Ondansetron Hcl	31	16
Torsemide	Torsemide	31	15
Cephalexin	Cephalexin	30	23
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	30	12
Lidocaine	Lidocaine	29	suppressed
Losartan Potassium	Losartan Potassium	29	14
Baclofen	Baclofen	28	suppressed
Jardiance	Empagliflozin	27	suppressed
Pregabalin	Pregabalin	25	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	25	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	25	18
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Famotidine	Famotidine	23	11
Methenamine Hippurate	Methenamine Hippurate	23	suppressed
Nitroglycerin	Nitroglycerin	23	11
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Spiriva Respimat	Tiotropium Bromide	22	11
Doxycycline Hyclate	Doxycycline Hyclate	21	17
Levetiracetam	Levetiracetam	21	suppressed
Methylprednisolone	Methylprednisolone	21	16
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Lorazepam	Lorazepam	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Clobetasol Propionate	Clobetasol Propionate	19	suppressed
Clonazepam	Clonazepam	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Phenobarbital	Phenobarbital	19	suppressed
Risperidone	Risperidone	19	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Fosfomycin Tromethamine	Fosfomycin Tromethamine	17	11
Hydrochlorothiazide	Hydrochlorothiazide	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	15	suppressed
Ammonium Lactate	Ammonium Lactate	15	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Vascepa	Icosapent Ethyl	15	suppressed
Anastrozole	Anastrozole	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Levofloxacin	Levofloxacin	14	12
Temazepam	Temazepam	14	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Polymyxin B Sul-Trimethoprim	Polymyxin B Sulf/Trimethoprim	13	suppressed
Santyl	Collagenase Clostridium Hist.	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Atenolol	Atenolol	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Linzess	Linaclotide	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Prevalite	Cholestyramine	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error